Technical Eye on Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)


Technical Indicators and Signals

The stochastic oscillator indicator is the important indicator to compare the security price over a certain period of time. The stochastic %K of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for the period of 9-Day stands at 10.1% while the stochastic %D for the same period stands at 9.33%.

The 7-Day Average Directional Index ADX (also known as Trend Strength Indicator) of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) signals “Sell” while other important signals like the 20-Day Moving Average Vs. Price signals “Sell”.

Another important signal of trend and momentum of a security is 20-50 Day MACD Oscillator or Moving Average Convergence Divergence signals “Buy” for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) while 20-100 Day MACD Oscillator indicates “Buy”.

Bollinger band is a volatility indicator of a certain security, currently Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)’s 20-Day Bollinger Band indicates “Hold”.

About Company

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics’ first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics’ first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.

Previous Day Activity Analysis

On the last trading day, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) opened the session at $6.56 and after going up 0.46% closed at $6.58. The stock gained 0.02 points in the last trade.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)’s stock fluctuated in the range of $6.41 and $6.63 during the previous active session. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) traded with the volume of 735217 with average volume of 1.09 Million. The stock has MEDIUM volatility on the last trading session.

Currently the Beta for the company remains at 3.54 while ATR (Average True Range) and RSI (Relative Strength Index) are at 0.32 and 44.31 respectively.

Currently the Insider Ownership of the shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) is at 0.31% and the shares outstanding are 72.91 Million.

Important Ratio Analysis

Some important ratios to consider here for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) are discussed below:

Dividend yield of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) stands at 0% whereas Price to Earnings P/E ratio stands at 0 while Forward P/E shows the value of 0.

The Price to Sale P/S and Price to Book P/B shows the value of 7.54 and 6.21 respectively. While Price to Cash P/C and Price to Free Cash Flow P/FCF stands at 4.21 and 137.07 correspondingly.

The Quick Ratio of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) stands at 7.3 while the Current Ratio depicts the value of 7.3.

Return on Assets ROA of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) is at -2.2% whereas, Return on Equity ROE and Return of Investment ROI of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) stand at -4.1% and 7.3% respectively.

Stock Performance Analysis

The stock performance of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) on the basis of 5 day trade show the dip of -7.97% whereas, the monthly performance of the stock shows decrease of -7.32%.

The quarterly performance of the stock remained in red zone with the value of -2.81% while six month performance of the shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) remained bearish with the count of -20.63%.

The yearly and YTD performance of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) remained mix at 15.03% and -23.84% respectively.